JAMA Neurology · 2017 · 53 citations · 15 references
MedicineEndocrinologyInternal MedicineClinical EpidemiologyDiabetologyGenetic CounselingDiabetes ManagementDiabetes MellitusMetabolic DiseaseDiabetes DiagnosisGenotype-phenotype AssociationsGlucose Metabolism DisordersGlucose Transport DefectsGlucose Transport DisordersImpaired Glucose TolerancePrognostic PredictionPrognostic Variables
Importance: Case reports regularly document unique or unusual aspects of glucose transporter type 1 deficiency (G1D). In contrast, population studies from which to draw global inferences are lacking. Twenty-five years after the earliest case reports, this deficiency still particularly affects treatment and prognostic counseling. Objective: To examine the most common features of G1D. Design, Setting, and Participants: In this study, data were collected electronically from 181 patients with G1D through a web-based, worldwide patient registry from December 1, 2013, through December 1, 2016. The study used several statistical methods tailored to address the age at onset of various forms of G1D, associated manifestations, natural history, treatment efficacy, and diagnostic procedures. These factors were correlated in a predictive mathematical model designed to guide prognosis on the basis of clinical features present at diagnosis. Results: A total of 181 patients with G1D were included in the study (92 [50.8%] male and 89 female [49.2%]; median age, 9 years; age range, 0-65 years). As previously known, a relatively large variety of common phenotypes are characteristic of the G1D syndrome, including movement disorders, absence epilepsy (typical and atypical), and myoclonic and generalized epilepsies. The 3 main novel results are (1) the feasibility of effective dietary therapies (such as the modified Atkins diet) other than the ketogenic diet, (2) the relatively frequent occurrence (one-fourth of cases) of white matter magnetic resonance imaging abnormalities, and (3) the favorable effect of early diagnosis and treatment regardless of treatment modality and mutation type. In fact, the most important factor that determines outcome is age at diagnosis, as reflected in a predictive mathematical model. Conclusions and Relevance: The results reveal several changing notions in the approach to G1D syndrome diagnosis and treatment, such as the perceived absolute requirement for a ketogenic diet, the assumed lack of structural brain defects, and the potential existence of genotype-phenotype correlations, all of which are contested by the registry data.
15
Imaging the metabolic footprint of Glut1 deficiency on the brain
Juan M. Pascual, Ronald L. Van Heertum, Dong Wang et al. · Annals of Neurology · 2002 · 153 citations
Glucose transporter 1 deficiency in the idiopathic generalized epilepsies
Todor Arsov, Saul A. Mullen, Sue Rogers et al. · Annals of Neurology · 2012 · 143 citations
Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency
Todor Arsov, Saul A. Mullen, John A. Damiano et al. · Epilepsia · 2012 · 115 citations · Full text
Use of dietary therapies amongst patients with GLUT1 deficiency syndrome
Hannah Kass, S. Parrish Winesett, Stacey K. Bessone et al. · Seizure · 2016 · 110 citations